For example, CD68+ and CD163+ macrophages have been demonstrated to exert different effects on the prognosis of stages I-III colon cancer patients, highlighting the importance of characterizing macrophage subtypes in CRC (37). The gene discussed is CD163; the disease is malignant colon neoplasm.